Exelixis signs two new collaboration agreements with BMS
Under the first agreement, Exelixis will grant to BMS an exclusive license to its small-molecule TGR5 agonist program including backups. Under the second agreement, the companies will collaborate
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.